In a study of 10 women with advanced osteoporosis, a single stem cell infusion was associated with a 94% drop in fragility fractures over two years, according to a report in Cell. The finding is preliminary given the small sample size.
In diabetes and obesity, Novo Nordisk's low-dose investigational CagriSema achieved 12.4% weight loss versus 9.1% for tirzepatide 5 mg in a phase III trial of adults with type 2 diabetes. Roche's enicepatide, an investigational dual agonist, produced 15.5% weight loss at 48 weeks in a phase II trial involving adults with obesity and diabetes.
A deep learning analysis of noncontrast chest CTs found that lower thoracic vertebral bone mineral density was linked to faster cognitive decline, especially in adults with diabetes, per a study in Radiology. The roundup also notes that the FDA convened an expert panel on testosterone therapy for menopausal women, and the Pentagon will resume its program testing troops' testosterone levels. Separately, the Justice Department announced that two hospital systems agreed to stop providing gender-affirming care for minors and pay over $9 million combined in fines, and dozens of patients have sued GLP-1 manufacturers over inadequate warnings about a rare vision condition.